Dr Lal PathLabs

While discounts have come down, pricing gap still large between incumbents and new players

While discounts have come down, pricing gap still large between incumbents and new players

Dr Lal PathLabs on Thursday said its consolidated profit after tax declined 7 per cent to Rs 54 crore for the December quarter. The company had reported a net profit of Rs 58 crore in the October-December quarter of the previous fiscal. Revenue also declined to Rs 489 crore for the period under review as compared with Rs 497 crore in the year-ago period, the company said in a regulatory filing. "We continue to focus on geographical expansion and strengthen our presence in Tier 2, Tier 3 towns. Our focus continues to take a higher market share in West and South markets by leveraging technology and promoting high-end super specialty test portfolios," Dr Lal PathLabs Managing Director Om Manchanda said. Shares of the company were trading 1.63 per cent down at Rs 2,019.15 apiece on the BSE.

Hospitals are expected to report a soft Q3 result due to a mix of seasonality and easing pent-up demand, however, average revenue per occupied bed is likely to remain steady

Om Manchanda, MD, Dr Lal Pathlabs said that the contribution of the west zone has gone up from 6 percent in FY15 to 8 percent in FY20 and 15 percent in the first half of FY23

Reports suggest that Union Health Minister Mansukh Mandaviya will review the Covid-19 pandemic situation, in view of a spurt in COVID-19 cases in Japan, South Korea, Brazil, China and the US.

Competitive pressures, valuations cap gains from current levels

Indian medical diagnostics firm Dr. Lal PathLabs Ltd on reported a 24.5% drop in September quarter profit as a sustained decline in revenue and volume from its Covid-19 related business

While domestic market demand is strong, analysts expect higher raw material and freight costs to affect business in US, other countries; healthy YoY growth seen in hospitals and diagnostics

Diagnostic services provider Dr Lal Path Labs on Thursday said its consolidated net profit declined 57 per cent to Rs 58 crore for the first quarter ended June 30

Experts believe the current news cycle may keep the stock prices of related players volatile in the near term, but any fundamental or direct impact, in the long run, remains improbable.

Thyrocare, Dr Lal Path Labs and Metropolis are trading almost 50 per cent below their respective all-time highs, the reversal may see breakout if the key respective levels are sustained

Competitive pressures, high valuations limit upsides for listed lab chains

Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country

In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 per cent in Q4FY21

Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line

Diagnostic services provider Dr Lal PathLabs on Tuesday said it has launched a pilot project to use drones for transporting blood samples. The use of drones would expand Dr Lal Pathlab's services to inaccessible locations, the company said in a statement. Pilot projects are being launched across multiple remote, semi-urban and rural locations to experiment multiple-use cases that eliminate challenges like congestion due to traffic, poor road conditions and inaccessibility, it added. "As the leader in diagnostic industry, Dr Lal PathLabs is committed towards integration of new technologies into its existing logistics systems to further expedite sample collections. The use of drones could significantly speed-up regular and emergency medical care in rural areas and help save lives," Dr Lal PathLabs Head Logistics & Home Collection Amit Aggarwal noted. The company is initiating pilot projects in different parts of the country. "If these first trial runs are successful, we are hopeful

Diagnostics chain Dr Lal PathLabs Ltd on Thursday reported a consolidated net profit of Rs 58.2 crore in the third quarter ended in December 2021. The company had posted a consolidated net profit of Rs 95.9 crore in the same quarter last fiscal, Dr Lal PathLabs said in a regulatory filing. Consolidated revenue from operations during the quarter under review stood at Rs 496.9 crore. It was at Rs 452.4 crore in the year-ago period, it added. The results include that of Suburban Diagnostics with effect from November 12, 2021, and hence is not strictly comparable with previous year, the company said. Covid and allied contributed 11.8 per cent to revenue in Q3 FY22 with 5.8 lakh RTPCR tests, it added. Total expenses during the third quarter were at Rs 427.5 crore, up from Rs 337 crore in the year-ago quarter, Dr Lal PathLabs said.

In a Q&A, Om Manchanda says the firm is now growing organically in the Southern market, but is open to inorganic opportunities there

Diagnostic services provider Dr Lal PathLabs on Tuesday posted a 10.6 per cent increase in its consolidated profit after tax (PAT) at Rs 96.3 crore for the second quarter ended September 30